RA Capital Management is a Boston-based investment firm specializing in healthcare, life sciences, and planetary health. It pursues evidence-based, science-led investing through its internal TechAtlas research engine and supports portfolio companies via its Raven healthcare incubator. The firm engages across stages from seed funding to IPOs and follow-on financings, focusing on drugs, medical devices, diagnostics, and other biomedical innovations, with a regional emphasis on the United States and Europe.

OrbiMed is a global healthcare investment firm based in New York, founded in 1989. It manages capital across public and private markets, including private equity, venture and growth investments, and private credit, with structured debt and royalty arrangements to support owners of intellectual property and diagnostics. The firm focuses on biopharmaceuticals, life sciences, medical devices, diagnostics, health IT, and healthcare services, investing from startups to multinational companies. With a worldwide team and offices in multiple regions, OrbiMed provides financing and strategic resources to advance therapies and healthcare innovations, aiming to improve patient outcomes across global markets.

The Invus Group is a long-standing private equity firm founded in 1985 and based in New York. It partners with entrepreneurs to drive transformative growth across sectors including consumer products and services, technology, life sciences, software, and industrials. The firm emphasizes long-term collaboration, aligns incentives with management, and provides both capital and strategic advisory to help portfolio companies scale internationally. It maintains a global presence with offices in the United States, Europe, and Asia, and pursues flexible investment approaches through evergreen capital structures and co-investment opportunities. The group supports management-led buyouts, growth equity, and select opportunistic investments, aiming to create lasting value rather than short-term gains.

Samsara BioCapital is a venture capital firm based in Palo Alto, California, founded in 2016. The firm focuses on the healthcare sector, investing in biotechnology companies across the United States and serving as an investment adviser to support the development of transformative therapeutics. By combining scientists, clinicians, drug developers, and business leaders with extensive experience, Samsara BioCapital aims to accelerate the next generation of therapies through collaborative partnerships and strategic capital. The firm operates as a principal investor and provides guidance to entrepreneurs seeking to turn their ideas into successful biotech ventures.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. It employs a multi-strategy platform spanning growth equity, private equity, venture capital, and public equity to invest in biopharmaceuticals, medical devices, diagnostics, and healthcare services. The firm backs companies at various stages and across regions, with a focus on the largest healthcare markets in the United States and China. Its multidisciplinary team includes physicians, scientists, entrepreneurs, and operating executives who work to advance patient care and drive growth. Vivo Capital has invested in hundreds of public and private healthcare companies worldwide and manages approximately $5.8 billion in assets.

The European Innovation Council is a European Union institution that funds and accelerates deep-tech innovation across Europe. It provides substantial support to startups, researchers, and technology transfer activities through programs such as the EIC Accelerator, EIC Fund, and EIC Prizes, and offers business acceleration services to help scale and globally expand ventures. The council is described as a major investor, providing about €6.5 billion in funding, and it co-invests with private investors in early-stage startups with ESG impacts. Established in 2018 and headquartered in Brussels, it focuses on breakthrough innovations in deep technology, including dual-use and defence-relevant technologies, and engages with innovation ecosystems through events, reports, and information hubs. The organization is oriented toward advancing European competitiveness by nurturing high-potential tech ventures from inception through scaleup.

TCG Crossover is a science-driven healthcare investment firm focused on advancing disruptive medicines and health technologies. It backs private and public companies led by entrepreneurs developing better treatment options for patients, with activity across the United States and Europe. The firm operates from Palo Alto and New York City and concentrates on healthcare, digital health, and health technology sectors.

Forbion is a global venture capital firm headquartered in Naarden, Netherlands, focused on life sciences and biotech, including human health and planetary health, with investments across early-stage and clinical-stage drug development, gene therapy, MedTech, and sustainable agriculture. It follows ESG principles in its investing and has a track record of supporting impactful innovations. The firm, with a team of over 35 professionals, has managed about €7.5 billion across multiple funds and has completed more than 140 investments. It operates through offices in the Netherlands, Germany, and the United States to support international activity.

Morningside Group is a venture capital firm based in Newton, Massachusetts, founded in 1986 as a family office for the Chan family. It pursues long-term investments in companies with novel science and technology, with active interest in life sciences, digital health, artificial intelligence, materials, and technology sectors. The firm emphasizes ethical business practices and seeks to support the growth of enduring companies. Beyond its investing activities, Morningside supports education, research, and healthcare through charitable commitments to institutions such as the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

New Enterprise Associates is a global venture capital firm founded in 1977 and based in Menlo Park, California. It provides capital and operational support to companies across development stages, from seed to IPO, with a focus on technology and healthcare sectors. The firm collaborates with founders to address technical challenges, offering domain expertise to assist product development and market expansion. NEA invests across the United States, Asia and Brazil, and its portfolio includes software, consumer technology, medical devices, life sciences, healthcare information technology, and energy technology companies. With a long track record of helping entrepreneurs achieve growth, NEA emphasizes enduring partnerships and strategic guidance alongside funding to build transformational businesses through multiple stages of a company lifecycle.

ARCH Venture Partners is a venture capital firm founded in 1986 and based in Chicago, Illinois, with additional operations in Seattle. The firm focuses on science-based companies, prioritizing life sciences and related technologies, and aims to translate academic and national lab innovations into commercially viable products. ARCH emphasizes a true partnership approach, providing capital alongside strategic guidance, expertise, and a broad professional network to founders. It has supported numerous companies across early to growth stages and is known for backing translational efforts that bring breakthrough discoveries to market, leveraging collaborations with researchers and entrepreneurs to accelerate development of disruptive technologies on a national and international scale.

Logos Capital is a biotechnology investment firm based in San Francisco, founded in 2019. It uses a disciplined, data-driven approach that combines in-house analytics with scientific and clinical expertise to identify transformative therapeutics. The firm conducts rigorous fundamental research across clinical, regulatory, operational, and commercial dimensions of drug development, leveraging a proprietary data science platform called Logos Analytics to assess clinical success probability. With an emphasis on risk management, Logos Capital aims to deliver long-term, uncorrelated returns through thorough due diligence and a holistic view of asset value.

Deep Track Capital is a venture capital firm headquartered in Greenwich, Connecticut. Founded in 2020, it concentrates on the life sciences and biotechnology sectors, investing in public and pre-IPO biotechnology companies. The firm emphasizes a hands-on partnership approach, providing capital, scientific expertise, and an extensive network to management teams. It seeks to lead transactions, form large syndicates, and participate in rounds led by other qualified investors, aiming to accelerate the development and commercialization of innovative biotech ventures.

Deerfield Management is a healthcare-focused investment firm that advances human health by investing in both public and private healthcare companies and by supporting research and development initiatives. The firm targets a broad range of healthcare sectors, including biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, and healthcare services. It seeks to create value through long-term capital deployment, collaboration with strategic partners, and its internal efforts to foster scientific research and drug discovery. In addition to investment activity, Deerfield operates philanthropic initiatives through the Deerfield Foundation that fund education, expanded healthcare access, and health-outcomes improvement.

Versant Ventures is a healthcare-focused venture capital firm based in San Francisco with a global footprint. Founded in 1999, it invests across the healthcare sector and all company stages, with emphasis on discovery and development of novel therapeutics, medical devices, and other life sciences ventures. The firm combines deep investment, operating, and scientific expertise to take a hands-on approach to building companies, drawing on in-house scientists and collaborations with leading academic institutions. Versant manages multiple funds and has a history of backing portfolio companies that achieve successful acquisitions or IPOs, reflecting a long track record in turning scientific advances into commercial ventures across North America and Europe.

Sofinnova Partners is a Paris-based independent venture capital firm focused on life sciences, investing from seed to later-stage in biopharmaceuticals, biotech, medical devices and related industrial biotech opportunities; it partners with entrepreneurs to develop transformative innovations, often taking a lead or cornerstone role, serving on portfolio company boards and guiding them from formation through exit. Founded in 1972, the firm emphasizes long-term partnerships and aims to advance scientific progress in healthcare and sustainability.

Omega Funds is a Boston-based venture capital firm founded in 2004 that focuses on investing in life sciences and related technologies. The firm targets opportunities in healthcare and biotech, including digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, with activity across North America and Western Europe. Omega Funds acts as a registered investment adviser, supporting early-stage and growth companies as they develop therapeutic and digital health solutions.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in early-stage biotechnology and life sciences companies. Founded in 1980, it focuses on translating breakthrough science into medicines and medical technologies, often employing a seed-led venture creation approach and taking lead investor roles with board representation. The firm operates with dedicated Life Sciences and Technology teams and invests across the United States and Europe, supporting startups through initial funding and early growth. Its portfolio emphasizes biopharmaceuticals, diagnostics, medical devices, and related platforms, reflecting a commitment to advancing innovative healthcare solutions.

SR One is the corporate venture capital arm of GlaxoSmithKline. It invests globally in life science companies pursuing innovative science with the potential to significantly improve medical care. Based in Redwood City, California, with a London office, SR One follows a back-and-build approach, partnering with founders to translate science into medicines. The firm evaluates opportunities across biotechnology, healthcare, medical devices, and related technology, focusing on companies with strong fundamentals and clear development plans. Its transatlantic presence provides access to high-quality science, strategic collaboration, and geographic reach to support portfolio companies as they advance therapies. SR One aims to accelerate the translation of scientific discovery into transformative treatments by acting as a strategic partner rather than a traditional investor.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It focuses on seed through early-stage investments and selected later-stage opportunities in life sciences and information technology across the United States and Europe. In life sciences, it backs clinical-stage pharmaceutical products, biotechnology, biopharmaceuticals, therapeutic drugs and medical technology platforms addressing unmet medical needs, with initial investments typically in the low millions and total commitments in the tens of millions; the firm often requires a board seat when leading or co-leading early rounds. In information technology, it supports product-oriented IT, enterprise software, service-provider software and telecommunications infrastructure across development stages. Sofinnova collaborates with entrepreneurs to secure initial funding, build teams, win customers and navigate acquisitions and IPOs, leveraging domain expertise to help portfolio companies scale globally. It does not invest in healthcare services, diagnostics, nutraceuticals or tool-kit ventures.

EcoR1 Capital is a venture capital firm based in San Francisco that invests in early-stage biotechnology companies developing innovative therapeutics. It applies a scientific approach, leveraging advances in molecular biology to identify promising ventures and support their pursuit of new medicines. The firm emphasizes partnering with entrepreneurs dedicated to therapeutic innovation and provides strategic and scientific guidance to help translate breakthrough discoveries into treatments for patients.

Commodore Capital is a New York-based venture capital firm focused on biopharmaceuticals. Founded in 2019, the firm concentrates on early-stage companies developing innovative therapies, with emphasis on genetic medicines and cellular therapies, during a period of rapid scientific advancement translating into clinical breakthroughs. It aims to be a supportive partner to smaller biopharmaceutical companies as they develop and deliver new medicines to patients globally.

SOSV is a global venture capital firm focused on early-stage deep-tech and cross-border software companies, investing primarily from pre-seed through growth stages. It accelerates product development, regulatory progress, fundraising, and commercial strategy by providing founders access to purpose-built labs, engineering spaces, and a broad physical and virtual infrastructure across multiple locations. The firm's program-driven approach combines selective funding with hands-on support, mentorship, and a wide network of co-investors and partners to help portfolio companies scale. SOSV operates a suite of specialized facilities for deep-tech founders, including incubation programs that connect startups with customers, researchers, and investors, and it emphasizes long-term relationships through ongoing operational and strategic assistance. While active globally, it maintains strong ties to Asia-focused cross-border markets and supports a diverse portfolio spanning bio-tech, hardware, robotics, software, and related fields.

HBM Healthcare Investments is a Swiss investment company focused on healthcare, managing a globally diversified portfolio of private and public healthcare companies. Based in Switzerland and established in 2001, the company targets opportunities across human medicine, biotechnology, diagnostics, and medical technology, seeking to benefit from demographic growth, medical advances, rising prosperity, and the increasing need for new therapies. The business emphasizes exposure to the rapidly expanding global healthcare market through a mix of private holdings, public investments, and related assets, aiming to generate value and long-term growth for investors.

Boxer Capital is a biotech investment firm and the corporate venture capital arm of Tavistock Group, based in San Diego, California. The firm invests in biotechnology and precision medicine companies across private and public markets, spanning the drug development lifecycle from early discovery to late-stage development and commercialization, with a focus on oncology and novel targets. It emphasizes scientific expertise and a disciplined, research-driven due diligence process that includes clinical, regulatory, and commercial assessment. Boxer Capital maintains independent investment decisions and has partnered with portfolio companies such as Mirati Therapeutics to support growth. The firm seeks opportunities in specialized medicine, precision oncology, and related life sciences sectors.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, including drug discovery and healthcare technology. It backs companies across the development spectrum, from early discovery to commercialization, with a long-term approach aimed at creating multiple product opportunities rather than quick exits. The firm manages substantial capital and operates an ecosystem of funds such as Platform, Opportunity, Labs-Soleil, and Crossover to support portfolio companies. Founded in 2007, The Column Group has generated significant returns for its partners and invested in numerous biotech ventures, including 55 companies with 18 exits. The organization emphasizes rigorous science, mentorship, and access to networks to advance portfolio programs in cancer, neurological, and other therapeutic areas.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across the lifecycle of a company, from inception to development and expansion. It supports therapeutic and medical innovations in Europe by investing across early-stage to growth opportunities and by collaborating with leading academic research institutions and hospitals. The firm manages multiple funds, including Kurma Biofund I, II and III, the Kurma Diagnostics fund, and the Kurma Growth Opportunities Fund, and invests in healthcare, life sciences, digital health, and related technology sectors.

Mission BioCapital is a life science venture capital firm that backs early-stage biotechnology and life sciences companies. With leadership that has a long history of founding and supporting dozens of startups, the firm operates from Cambridge, Massachusetts and San Francisco, California, leveraging a network of researchers and venture capital partners. It provides mentorship, collaboration, and hands-on support from concept through clinical trials, including access to shared laboratory space through its Platinum Program, which offers up to $500,000 in funding, a lab bench, and related services for promising startups. The firm focuses on accelerating scientific solutions and actively participates in portfolio company growth across therapeutic areas, backing companies through multiple funds.

BioVenture is a Suzhou-based investment firm focused on early and growth-stage healthcare in the life sciences sector with a global outlook. Since its founding in 2013, it has invested in more than 200 life sciences companies across four core areas—new drug discovery, medical devices, diagnostics and precision medicine, and healthcare services—with 19 portfolio companies having gone public on HKEX or the STAR Market. The firm operates four platforms—pharma/biotech, devices, diagnostics and precision medicine, and medical services—leveraging extensive industry resources and partnerships to drive portfolio growth. It emphasizes post-investment management and value-added services, supported by a team of experienced investment professionals and senior scientific advisors. Through a platform network anchored in bioBAY at Suzhou Industrial Park, BioVenture is regularly recognized among China’s top healthcare venture capital firms and remains active in funding innovative medical and pharmaceutical ventures.

MPM BioImpact is a venture capital firm focused on building and funding biotechnology companies to transform patient outcomes by developing innovative medicines. Based in Boston, the firm brings more than three decades of experience in translating scientific research into clinical impact and pursues opportunities across the biotechnology, healthcare, and life sciences sectors in the United States. It supports the full drug development process, from discovery through clinical proof of concept and regulatory milestones, with emphasis on areas such as oncology, immunology, neuroscience, and mental health. MPM BioImpact combines deep scientific expertise with strategic leadership to help portfolio companies navigate development challenges and accelerate patient-ready therapies. The firm has backed notable companies across its focus areas, leveraging hands-on guidance and collaboration to translate science into meaningful medical advances.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and first-round investments in technology and healthcare, with a broad remit across information technology, life sciences, media, energy, and emerging tech. The firm backs early- and growth-stage companies and has supported a number of notable portfolio companies, including Apple Computer, Intel, Illumina, Gilead Sciences, Endeca, Imperva, DoubleClick, Athenahealth, Centocor, Check Point Software, Nest, SlideShare, and Tudou. Venrock emphasizes partnering with entrepreneurs to build enduring companies and leverages its long history in technology and healthcare to help founders navigate growth, strategy, and complex markets.

Pontifax is a healthcare-focused investment firm headquartered in Herzliya, Israel. It concentrates on life sciences and healthcare technologies, supporting companies across development stages with an emphasis on innovative biopharma, medical devices, biotechnology, and related sectors. The firm seeks to back transformative ideas through hands-on guidance and strategic support, aiming to help early-stage ventures grow and accelerate commercialization. While investing globally, Pontifax maintains a strong Israel focus and has built a portfolio spanning pharmaceuticals, diagnostics, and related fields, with a history dating to its founding in 2004.

Casdin Capital is a New York-based venture capital and investment firm focused on the life sciences and healthcare sectors. Founded in 2012 by Eli Casdin, the firm backs companies across genomic research, molecular medicine, precision medicine, diagnostics, synthetic biology, oncology, digital health, and related technologies. It pursues a data-driven, long-term investment approach and seeks to form strong partnerships with portfolio companies to advance scientific innovation and improve patient outcomes. The firm engages with ventures at various stages, from early- to late-stage private companies, emphasizing opportunities at the intersection of biology and technology. Through its activity in life sciences and healthcare, Casdin Capital positions itself as a partner to founders pursuing breakthroughs in genomics, molecular medicine, and AI-enabled healthcare platforms.

Khosla Ventures is a California-based venture capital firm founded in 2004 that backs technology-driven startups across multiple sectors, including artificial intelligence, healthcare, sustainability, digital health, and consumer technology. The firm provides capital and strategic guidance to companies at early and growth stages, with an emphasis on disruptive technologies and world-changing businesses. It operates a range of funds, including seed and later-stage vehicles, and maintains a broad investment thesis that covers AI, climate tech, energy efficiency, and other high-potential areas, primarily focused in the United States. The firm is known for working closely with entrepreneurs to build long-lasting companies.

Alumni Ventures is a venture capital firm that provides accredited investors access to venture-stage and late-stage private market investments. It offers funds, syndicates, investing clubs, and co-investment opportunities with established venture capital firms, and it provides venture investing education through AV Academy along with resources for startup founders.

venBio Partners is a California-based venture capital firm focused on life sciences, investing in U.S. companies from early to late stages with an emphasis on novel therapeutics and drug discovery. The firm typically leads investments and builds syndicates, applying hands-on involvement to optimize development programs and strategic positioning. venBio emphasizes strong intellectual property, robust chemistry, manufacturing and controls, and comprehensive clinical development plans, including trial design, endpoints, powering, and regulatory considerations, to help portfolio companies meet potential partner and acquisition criteria from the outset. It seeks to improve patient care through its portfolio and aims to form lasting relationships with leaders in the life sciences sector, with offices in San Francisco and Seattle and global operations.

Lumira Ventures is a North American life sciences and healthcare venture capital firm with offices in Toronto, Montreal, Vancouver and Boston. It partners with entrepreneurial management teams to build innovative biotherapeutic, medical device, digital health and consumer health companies that address meaningful unmet needs. Since its inception, Lumira Ventures has invested in more than 100 healthcare companies and currently supports a portfolio of over 30 active investees across Canada and the United States. The firm focuses on early- to late-stage venture opportunities, providing financings, active board participation and help with access to additional funding, strategic partnerships and market channels to maximize the value of technology pipelines. The organization aims to drive transformational impact in patient care through its portfolio companies.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 that provides seed- and early-stage capital to life sciences companies. The firm focuses on biopharmaceuticals, medical devices and instruments, digital health, and related health technologies, with an emphasis on early-stage private therapeutics and other life science ventures in the United States. It supports early rounds such as Series A and collaborates with academics, researchers, and entrepreneurs to advance proof-of-concept data and development programs. The company operates primarily from its San Francisco headquarters and maintains a presence in Boston, reflecting its national investment scope. It runs initiatives to discover and incubate breakthrough science through internal programs designed to accelerate translational work and product progress. Overall, 5AM Ventures aims to help promising healthcare and life science companies grow from concept to commercialization.

Third Rock Ventures is a Boston-based venture capital firm founded in 2007 that invests in life sciences and healthcare companies, including biotechnology, medical devices, diagnostics, therapeutics, and related information technology. The firm targets early-stage and growth opportunities, frequently leads rounds, and takes an active role in portfolio companies, often pursuing strategic collaborations with larger pharmaceutical and biotechnology partners to advance medicines and technologies. Its focus spans oncology, autoimmune diseases, genetic disorders, and other therapeutic areas with the aim of improving patient outcomes through innovative drug development and diagnostics.

Ally Bridge Group is a global life sciences investment firm founded in 2013 and headquartered in New York, with a presence in Asia and Europe. It focuses on healthcare, biotechnology, medical technology, and related disruptive platforms, investing across private equity, venture, growth, and select public equities. The firm targets companies at early to development stages and aims to support transformative advances in drugs, diagnostics, medical devices, and related technologies. It emphasizes scientific and commercial conviction, proprietary research, and board-level engagement to help portfolio companies advance patient care, reduce costs, and expand global reach. Through its network, Ally Bridge Group collaborates with innovators to bridge research and commercialization, seeking meaningful impact beyond capital.

Pivotal bioVenture Partners is a San Francisco–based venture capital firm focused on life sciences, including therapeutics, medical devices, diagnostics, and related platforms. Founded around 2017, the firm invests in privately held companies across North America and Europe, and maintains a China presence to support opportunities in Greater China. The team combines venture investing experience with drug discovery, development, and company-building expertise to back early- through late-stage ventures and to provide strategic guidance. The firm operates globally with offices in San Francisco, Shanghai, and Hong Kong, and is affiliated with Nan Fung Life Sciences, reflecting a broader platform that supports transformative therapies and healthcare innovations.

Abingworth is an international life sciences investment firm founded in 1973 with offices in London, Boston, and Menlo Park. It collaborates with life sciences entrepreneurs to develop ideas into products that significantly impact health, investing across all development stages from startups to publicly traded companies and across all life sciences sectors. Supported by a team of 27 professionals, the firm has over $1 billion under management and has invested in 142 life science companies, with 60 IPOs and 40 mergers and acquisitions completed.

Catalio Capital Management is a New York-based investment firm focused on the full lifecycle of innovative healthcare companies across private, public, and credit markets. It pursues a multi-asset approach, including venture capital, structured opportunities, public equities, and co-investments, to back life sciences and technology-driven companies at various stages and capital structures. As of 2025, Catalio manages about $2 billion in assets and employs over 40 professionals across New York, Washington, DC, and London, supported by a network of roughly 45 venture partners who provide proprietary deal flow and domain expertise. The firm concentrates investments in drugs, AI-enabled technologies, and devices, and seeks strategic exits alongside ongoing value creation. Catalio emphasizes scientific leadership and collaboration with world-class scientists-entrepreneurs, aiming to translate breakthrough research into scalable healthcare solutions.

Aisling Capital is a New York-based venture capital and private equity firm founded in 2000 that specializes in healthcare and life sciences. The firm backs late-stage and growth companies developing innovative therapeutics, diagnostics, and medical technologies across the United States, Canada, and Western Europe, with a focus on advancing products to commercialization. Its portfolio has included companies across areas such as biotechnology, neuroscience, and regenerative medicine, and it seeks to support companies through capital and strategic guidance to translate scientific breakthroughs into patient care.

Medicxi is a venture capital firm focused on the life sciences sector. Founded in 2016 by the former Index Ventures life sciences team, the firm is based in London, United Kingdom, with additional offices in Geneva and Jersey. Medicxi invests across seed, early, and later stages in Europe, targeting therapeutics, biotech, and technology-enabled healthcare companies. Building on decades of experience in drug discovery and development, the team supports ventures across a broad range of therapeutic areas, including vaccines, oncology, and neurology, helping firms advance research, development, and commercialization. The firm originated from Index Ventures and continues to back ambitious startups seeking to translate scientific advances into patient benefit, leveraging a hands-on approach and a network of biopharma partnerships.

U.S. Venture Partners is a venture capital firm based in Menlo Park, California, founded in 1981. It specializes in early-stage investments in information technology and healthcare, supporting entrepreneurs in areas such as enterprise software, IT security, consumer internet, mobile, e-commerce, and IT-enabled healthcare services. The firm is composed of former entrepreneurs, technologists, and industry professionals who work with startups to develop and scale their businesses.

Longitude Capital is a venture growth investment firm focused on life sciences, including biotechnology, medical technology, and health solutions. Established in 2006 and based in Menlo Park, California, it targets clinically de-risked assets across private and public life-science companies. The firm seeks to build balanced portfolios of clinical-stage and commercial-stage assets with attractive risk-adjusted returns within three to five years. It relies on a broad industry network and thematic research to identify opportunities in emerging therapeutic areas, and employs a range of investment structures such as traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open-market purchases, royalties, and other equity-linked instruments. The firm emphasizes strategic partnerships to support portfolio companies through fundraising and liquidity events.

IMM Private Equity is an independent private equity firm based in Seoul, South Korea, specializing in significant minority investments and middle-market buyouts. Established in 2006, the firm concentrates on Korea-related opportunities and typically pursues active roles in portfolio companies to drive value. Its investment focus spans growth capital, turnaround, mezzanine, and buyout transactions across sectors such as manufacturing, information technology, healthcare and biotechnology, and consumer-related industries, with additional cross-border opportunities in Asia. The firm benefits from a longstanding network of institutional investors and a disciplined investment approach that emphasizes rigorous analysis and value creation through operational improvements. IMM Private Equity operates within the IMM group, a holding and capital management platform that includes affiliated private equity and credit activities, leveraging integrated relationships and experience across Korea’s evolving private capital market.

Seventure Partners is a Paris-based venture capital firm that actively funds and supports technology and life sciences companies across Europe and beyond. It focuses on Life Sciences, including microbiome, nutrition, wellbeing, medical devices, digital health, pharmaceuticals, industrial biotech and animal health, and on Digital Technologies such as Fintech, Retailtech, cybersecurity, B2B software, hardware, telecom, sport tech and IoT, while also investing in blue economy sectors like sustainable aquaculture, biopolymers and bioproducts, recycling and climate solutions. Founded in 1997, the firm manages about €1 billion and operates from European hubs to provide hands-on guidance that aims to accelerate growth and market leadership for ambitious portfolio companies. The firm targets opportunities across Europe, North America and other regions, partnering with entrepreneurs to scale globally.

Ysios Capital is a Spanish independent venture capital firm focused on life sciences and human healthcare. Founded in 2008 and based in Donostia-San Sebastián, it manages roughly €350 million to €400 million across dedicated funds and backs early- and mid-stage companies developing novel therapies, diagnostics, medical devices, and platform technologies across Europe and North America. The firm supports development through scientific and entrepreneurial guidance, often taking board seats, and seeks to finance product development and breakthrough innovations with the aim of helping patients and delivering growth for portfolio companies. Exits are typically pursued through mergers, acquisitions, or public offerings, reflecting a disciplined, long-term approach to value creation in the life sciences and healthcare sectors.